NVMDF News and Press, Novamind Inc. From 11/05/21

Industry-leading revenue, $6,069,247 in FY2021 Total working capital of $9,680,431 to fund operations­­ Expanded network to six clinics and three clinical research sites Contracted for eight clinical trials Granted DEA Schedule 1 licenses for psilocybin researc...

TORONTO, ON / ACCESSWIRE / November 4, 2021 /  Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced that it is the subject of a failure-to-file cease tra...

TORONTO, ON / ACCESSWIRE / October 22, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to unveil Alto Neuroscience ("Alto"), a clinical-stage biopharmaceutical company, as its...

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...

It’s time for your Daily Hit of cannabis financial news for October 13, 2021. On The Site MJ Biz If you are a first-time attendee at the MJ Biz conference or even if you are a veteran, we are going to try to help streamline your time at the event. Gree...

Licenses a key step in hosting contracted clinical trials for Schedule 1 controlled substances TORONTO, ON / ACCESSWIRE / October 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine ...

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestor...

TORONTO, ON / ACCESSWIRE / October 8, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced participation in two upcoming virtual investor conferences on Wednesday, October 13,...

Specialized program to research and scale access to psychedelic medicine opens new doors for patients with chronic and serious illness TORONTO, ON / ACCESSWIRE / October 7, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health compa...

Chief Medical Officer will join expert panel on data and tech in psychedelic-assisted psychotherapy TORONTO, ON / ACCESSWIRE / October 4, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medic...